Our publications

Newsletters:

Q3-2015 review

http://members.viplus.com/view.ashx?message=e40515376O23610284O181697O23645629&r=1

 

Q2-2015 review

http://members.viplus.com/view.ashx?message=e40482187O24873862O181697O24839575&r=1

 

 

 

Articles:

 

Portola - Driving The Shift In The Anticoagulant Market

http://seekingalpha.com/article/3956723-portola-driving-shift-anticoagulant-market

 

Solithromycin From Cempra Is Positioning To Be The Treatment Of Choice For CABP

http://seekingalpha.com/article/3612846-solithromycin-from-cempra-is-positioning-to-be-the-treatment-of-choice-for-cabp

 

The $4Bn Patient: Will Dynavax's Study Finally Remove Safety Doubts From Heplisav?

http://seekingalpha.com/article/3435886-the-4bn-patient-will-dynavaxs-study-finally-remove-safety-doubts-from-heplisav

 

Fishing For A Cancer Drug With Exelixis

http://seekingalpha.com/article/3284565-fishing-for-a-cancer-drug-with-exelixis

 

How Successful Was The Neuralstem Phase II Trial?

http://seekingalpha.com/article/3006336-how-successful-was-the-neuralstem-phase-ii-trial

 

Will Neuralstem Phase II Results Pave The Road To A Stem Cell Cure For ALS?

http://seekingalpha.com/article/2927166-will-neuralstem-phase-ii-results-pave-the-road-to-a-stem-cell-cure-for-als

 

Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic

http://seekingalpha.com/article/2747685-spin-doctors-data-and-market-projections-from-aerie-pharmaceuticals-inc-are-too-optimistic